Table 2.

Association between early development of influenza-like adverse events of interest and later recurrence

VES treatment	Onset of flu-like AEI before dose 4	No flu-like AEI after dose 4 and beyond, N	Any flu-like AEI after dose 4 and beyond, N	P value
Received dose 1, participants [N = 363]		311	52
	Participants with any flu-like AEI after dose 1 and before dose 2	14/311 (5%)	12/52 (23%)	P < 0.001
Received dose 2, participants [N = 360]		308	52
	Participants with any flu-like AEI after dose 2 and before dose 3	14/308 (5%)	8/52 (15%)	P < 0.01
Received dose 3, participants [N = 358]		306	52
	Participants with any flu-like AEI after dose 3 and before dose 4	6/306 (2%)	7/52 (14%)	P < 0.001

Nominal P values generated from chi-square test

AEI adverse events of interest, flu-like AEIs influenza-like adverse events of interest, VES vesatolimod